Europäische Union - Spanisch - EMA (European Medicines Agency)

elanco gmbh - lotilaner, milbemycin oxime - endectocidas - perros - for use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - eprinomectina - solución tópica pour on - eprinomectina 0.5 g;excipientes c.s.p , eprinomectina 0.5 g; excipientes c.s.p - antiparasitarios de uso externo: acaricidas, cutáneos (microfilarias, larvas, gusaneras, nuches), reguladores del crecimiento (larvas/huevos), garrapatas, piojos, pulgas. - caprinos, equinos, ovinos, vacunos, conejos - indicado por ser altamente eficaz para el tratamiento y el control de endoparásitos y ectoparásitos. apropiado para el tratamiento y control de las infecciones parasitarias causadas por formas maduras e inmaduras de nemátodes gastrointestinales y pulmonares, tábanos, moscas, piojos chupadores y masticadores, chorioptes spp., psoroptes spp. y sarcoptes spp. (ácaros de la sarna), entre otros.

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biovet perú - closantel; - suspensión oral - closantel 10 g; excipientes c.s.p - antiparasitarios internos; gastrointestinales (nematodos); hepáticos (trematodos-fasciola) - camelidos; equinos; ovinos; vacunos - nemátodes gastrointestinales; tremátodes, infestaciones; nemátodes, infestaciones; infestación por fasciola

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biovet perú - closantel - suspensión oral - closantel 10 g;excipientes c.s.p , closantel 10 g; excipientes c.s.p - antiparasitarios internos: gastrointestinales (nematodos), hepáticos (trematodos-fasciola). - camelidos, equinos, ovinos, vacunos - bovinos: nemátodos (adultos y formas larvarias l3 y l4 de: haemonchus spp., bunostomum spp., oesophagostomum spp. trichostrongylus spp., ostertagia spp, chabertia spp.). tremátodos (fasciola hepatica, paramphistomum spp.). ectoparásitos: dermatobia hominis, haematopinus eurysternus, solenoptes capillatus, lignonathus vitulli. preventivo de la cochliomyia hominivorax y de la callitroga spp. ovinos y camélidos: nemátodos (adultos y formas larvarias l3 y l4 de: haemonchus spp., bunostomum spp., oesophagostomum spp., cooperia spp., trichostrongylus spp., ostertagia spp.). tremátodos (fasciola hepatica, fasciola gigantica, paramphistomum spp.) . ectoparásitos: melophagus ovinus, oestrus ovis. preventivo de la cochliomyia spp. o callitroga spp. equinos: endoparásitos (strongylus vulgaris, strongylus equinus, strongylus edentatus, triodontophorus spp., parascaris equorum, oxiurus equi, anaplocephala perfoliata; estadios larvarios de gasterophilus nasalis, gasterophilus intestinalis.

Europäische Union - Spanisch - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - agentes antineoplásicos - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. los pacientes con egfr o alk positivo tumor mutaciones debe también han recibido terapia dirigida antes de recibir keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Spanien - Spanisch - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

abbvie as - levodopa, carbidopa - excipientes: carmelosa sodica - agentes dopaminÉrgicos - dopa y derivados de la dopa - levodopa con inhibidor de la descarboxilasa

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - abamectina - solución tópica pour on - abamectina 1 g;excipientes c.s.p , abamectina 1 g; excipientes c.s.p - antiparasitarios internos: gastrointestinales (nematodos), pulmonares – traqueales, renales. antiparasitarios de uso externo: acaricidas, cutáneos (microfilarias, larvas, gusaneras, nuches), reguladores del crecimiento (larvas/huevos), garrapatas, piojos. - camelidos, caprinos, ovinos, porcinos, vacunos - para el tratamiento y control de parasitosis internas (nematodos gastrointestinales, pulmonares y renales) y externas (estados larvarios de dípteros causantes de miasis, piojos chupadores, ácaros productores de sarna, mosca de los cuernos, gusano de la nariz; ayuda en el control de garrapatas y piojos masticadores). con acción contra cepas resistentes a la ivermectina y otros endectocidas.

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - albendazol; alcanfor; cobalto, sulfato; eter medicinal; neomicina, sulfato; tetraciclina clorhidrato; vitamina a; vitamina b12; vitamina d3 (colecalciferol); vitamina e (a-tocoferol); vitamina k3 (menadiona) - suspensión oral - albendazol 15 g;alcanfor 20 g;cobalto, sulfato 0.98 g;eter medicinal 6 g;neomicina, sulfato 15 g;tetraciclina clorhidrato 7 g;vitamina a 400000 u.i.;vitamina b12 0.6 mg;vitamina d3 (colecalciferol) 60000 u.i.;vitamina e (a-tocoferol) 200 u.i.;vitamina k3 (menadiona) 200 mg;excipientes c.s.p , albendazol 15 g; alcanfor 20 g; cobalto, sulfato 0.98 g; eter medicinal 6 g; neomicina, sulfato 15 g; tetraciclina clorhidrato 7 g; vitamina a 400000 u.i.; vitamina b12 0.6 mg; vitamina d3 (colecalciferol) 60000 u.i.; vitamina e (a-tocoferol) 200 u.i.; vitamina k3 (menadiona) 200 mg; excipientes c.s.p - antiparasitarios internos: gastrointestinales (nematodos), hepáticos (trematodos-fasciola), pulmonares – traqueales, tenias (cestodos). minerales (macroelementos, microelementos y oligoelementos): asociados. - camelidos, caprinos, ovinos, vacunos - control y tratamiento contra nematodos gastrointestinales, pulmonares, tenias y fasciolas adultas. incluye cobalto que ofrece una acción directa en prevención de anemias.

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - albendazol - suspensión oral - albendazol 20 g;excipientes c.s.p , albendazol 20 g; excipientes c.s.p - antiparasitarios internos: gastrointestinales (nematodos), hepáticos (trematodos-fasciola), pulmonares – traqueales, tenias (cestodos). - camelidos, caprinos, equinos, ovinos, vacunos - control y tratamiento contra nematodos gastrointestinales, pulmonares, tenias y fasciolas adultas.

Peru - Spanisch - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - ivermectina - solución inyectable - ivermectina 1 g;excipientes c.s.p , ivermectina 1 g; excipientes c.s.p - antiparasitarios internos: gastrointestinales (nematodos), pulmonares – traqueales. antiparasitarios de uso externo: acaricidas, garrapatas, piojos. - camelidos - para el tratamiento y control de parasitosis internas (nematodos gastrointestinales y pulmonares) y externas (piojos chupadores, garrapatas y ácaros productores de sarna) en alpacas. pruebas de campo han demostrado su efectividad contra la sarna hasta por lo menos 72 días posteriores a su aplicación.